CYP2C9*13

Revision as of 18:15, 7 January 2009 by Swilliams (talk | contribs)
Jump to navigation Jump to search

WikiDoc Resources for CYP2C9*13

Articles

Most recent articles on CYP2C9*13

Most cited articles on CYP2C9*13

Review articles on CYP2C9*13

Articles on CYP2C9*13 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on CYP2C9*13

Images of CYP2C9*13

Photos of CYP2C9*13

Podcasts & MP3s on CYP2C9*13

Videos on CYP2C9*13

Evidence Based Medicine

Cochrane Collaboration on CYP2C9*13

Bandolier on CYP2C9*13

TRIP on CYP2C9*13

Clinical Trials

Ongoing Trials on CYP2C9*13 at Clinical Trials.gov

Trial results on CYP2C9*13

Clinical Trials on CYP2C9*13 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on CYP2C9*13

NICE Guidance on CYP2C9*13

NHS PRODIGY Guidance

FDA on CYP2C9*13

CDC on CYP2C9*13

Books

Books on CYP2C9*13

News

CYP2C9*13 in the news

Be alerted to news on CYP2C9*13

News trends on CYP2C9*13

Commentary

Blogs on CYP2C9*13

Definitions

Definitions of CYP2C9*13

Patient Resources / Community

Patient resources on CYP2C9*13

Discussion groups on CYP2C9*13

Patient Handouts on CYP2C9*13

Directions to Hospitals Treating CYP2C9*13

Risk calculators and risk factors for CYP2C9*13

Healthcare Provider Resources

Symptoms of CYP2C9*13

Causes & Risk Factors for CYP2C9*13

Diagnostic studies for CYP2C9*13

Treatment of CYP2C9*13

Continuing Medical Education (CME)

CME Programs on CYP2C9*13

International

CYP2C9*13 en Espanol

CYP2C9*13 en Francais

Business

CYP2C9*13 in the Marketplace

Patents on CYP2C9*13

Experimental / Informatics

List of terms related to CYP2C9*13

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [6] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Cytochrome P450 2C9 (CYP2C9), a member of the CYP2C enzyme subfamily, ranks amongst the most important drug metabolizing enzymes in humans.

Human CYP2C9 has been shown to exhibit genetic polymorphism. In addition to the wild-type protein CYP2C9*1, at least 30 single nucleotide polymorphisms (SNPs) have been reported within the coding region of the CYP2C9 gene producing the variant allozymes. CYP2C9*13 is one of them. It involves a T-to-C transversion at nucleotide position 269 causing a mutation at codon 90, which results in a Leu->Pro substitution. Frequency analysis in 147 unrelated Chinese males indicated approximately 2% of the Chinese population carry the allele.[1][2] CYP2C9*13 was found in Japanese and Korean[3][4], too.

CYP2C9*13 allele was correlated with reduced plasma clearance of drugs that are substrates for CYP2C9.[5][6][7]

CYP2C9*13 was found by Si Dayong[7], Zhou Hui*[8], Zhang Yifan and Zhong Dafang[9]* in 2004.

References

  1. Si Dayong, Guo Yingjie, Zhang Yifan, Yang Lei, Zhou Hui*, Zhong Dafang. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics. 2004 Jul;14(7):465-9. [1]
  2. Zhang Yifan, Zhong Dafang*, Si Dayong, Guo Yingjie, Chen Xiaoyan, Zhou Hui. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. The British Journal of Clinical Pharmacology. 2005 Jan;59(1):14-7.[2]
  3. Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol. 2005 Oct;60(4):418-22
  4. Tong YIN, Keiko MAEKAWA, Kei KAMIDE, Yoshiro SAITO, Hironori HANADA, Kotaro MIYASHITA, Yoshihiro KOKUBO, Yasuhisa AKAIWA, Ryoichi OTSUBO, Kazuyuki NAGATSUKA, Toshiho OTSUKI, Takeshi HORIO, Shin TAKIUCHI, Yuhei KAWANO, Kazuo MINEMATSU, Hiroaki NARITOMI, Hitonobu TOMOIKE, Jun-ichi SAWADA, and Toshiyuki MIYATA1), Genetic Variations of CYP2C9 in 724 Japanese Individuals and Their Impact on the Antihypertensive Effects of Losartan, Hypertens Res Vol. 31, No. 8 (2008), 1149-57
  5. Guo Yingjie, Zhang Yifan, Wang Ying, Chen Xiaoyan, Si Dayong, Zhong Dafang, Fawcett JP, Zhou Hui*. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in human. Drug Metab Dispos. 2005 Jun;33(6):749-53.[3]
  6. Guo Yingjie, Wang Ying, Si Dayong, Fawcett PJ, Zhong Dafang, Zhou Hui*. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica 2005 Sep 1;35(9):853-861.[4]
  7. Zhou Yihan; Zheng Qingchuan; Li Zesheng*; Zhang Yuan; Sun Miao; Sun Chia-Chung; Si Dayong; Cai Lei; Guo Yingjie; Zhou Hui*, On the human CYP2C9 variant *13 activity reduction: a molecular, dynamics simulation and docking study, Biochimie, 2006 Volume 88, Issue 10, :1457-1465 [5]

{{SIB

Template:WH Template:WS